Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company provides cough and phlegm, kidney, anti-infection, cardiovascular and cerebrovascular, and digestive system drugs, as well as pediatrics, dermatology, tuberculosis, res… Read more
Teyi Pharmaceutical Group Co Ltd (002728) - Total Assets
Latest total assets as of September 2025: CN¥2.22 Billion CNY
Based on the latest financial reports, Teyi Pharmaceutical Group Co Ltd (002728) holds total assets worth CN¥2.22 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Teyi Pharmaceutical Group Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Teyi Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Teyi Pharmaceutical Group Co Ltd's total assets of CN¥2.22 Billion consist of 39.6% current assets and 60.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.1% |
| Accounts Receivable | CN¥214.70 Million | 8.9% |
| Inventory | CN¥264.38 Million | 11.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥156.04 Million | 6.5% |
| Goodwill | CN¥517.60 Million | 21.6% |
Asset Composition Trend (2009–2024)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Teyi Pharmaceutical Group Co Ltd's current assets represent 39.6% of total assets in 2024, a decrease from 68.9% in 2009.
- Cash Position: Cash and equivalents constituted 19.1% of total assets in 2024, up from 10.3% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 10.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 21.6% of total assets.
Teyi Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Teyi Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Teyi Pharmaceutical Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Teyi Pharmaceutical Group Co Ltd generates 0.29x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Teyi Pharmaceutical Group Co Ltd generates $ 0.85 in net profit.
Teyi Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 1.46 | 1.06 |
| Quick Ratio | 1.33 | 1.06 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥383.44 Million | CN¥ 332.49 Million | CN¥ 51.00 Million |
Teyi Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Teyi Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.22 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | CN¥2.40 Billion |
| Market Capitalization | $450.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Teyi Pharmaceutical Group Co Ltd's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Teyi Pharmaceutical Group Co Ltd's assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Teyi Pharmaceutical Group Co Ltd (2009–2024)
The table below shows the annual total assets of Teyi Pharmaceutical Group Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.40 Billion | -4.45% |
| 2023-12-31 | CN¥2.51 Billion | -1.30% |
| 2022-12-31 | CN¥2.55 Billion | +23.20% |
| 2021-12-31 | CN¥2.07 Billion | -8.42% |
| 2020-12-31 | CN¥2.26 Billion | -0.03% |
| 2019-12-31 | CN¥2.26 Billion | +9.15% |
| 2018-12-31 | CN¥2.07 Billion | +7.19% |
| 2017-12-31 | CN¥1.93 Billion | +20.32% |
| 2016-12-31 | CN¥1.60 Billion | +0.32% |
| 2015-12-31 | CN¥1.60 Billion | +93.57% |
| 2014-12-31 | CN¥825.60 Million | +82.03% |
| 2013-12-31 | CN¥453.54 Million | +16.83% |
| 2012-12-31 | CN¥388.22 Million | +37.08% |
| 2011-12-31 | CN¥283.21 Million | +12.06% |
| 2010-12-31 | CN¥252.73 Million | +33.26% |
| 2009-12-31 | CN¥189.65 Million | -- |